Jones Financial Companies Lllp Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN)

Jones Financial Companies Lllp increased its stake in Amgen Inc. (NASDAQ:AMGN - Free Report) by 19.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 22,300 shares of the medical research company's stock after buying an additional 3,593 shares during the quarter. Jones Financial Companies Lllp's holdings in Amgen were worth $5,812,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Unionview LLC increased its stake in Amgen by 3.8% in the third quarter. Unionview LLC now owns 876 shares of the medical research company's stock worth $282,000 after purchasing an additional 32 shares during the period. Avidian Wealth Enterprises LLC increased its stake in Amgen by 0.6% in the third quarter. Avidian Wealth Enterprises LLC now owns 5,863 shares of the medical research company's stock worth $1,889,000 after purchasing an additional 33 shares during the period. Beacon Financial Advisory LLC increased its stake in Amgen by 4.6% in the third quarter. Beacon Financial Advisory LLC now owns 769 shares of the medical research company's stock worth $248,000 after purchasing an additional 34 shares during the period. Semus Wealth Partners LLC increased its stake in Amgen by 2.3% in the third quarter. Semus Wealth Partners LLC now owns 1,531 shares of the medical research company's stock worth $493,000 after purchasing an additional 35 shares during the period. Finally, Connable Office Inc. increased its stake in Amgen by 0.5% in the third quarter. Connable Office Inc. now owns 6,972 shares of the medical research company's stock worth $2,246,000 after purchasing an additional 37 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total transaction of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company's stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total value of $2,585,603.09. Following the sale, the executive vice president now directly owns 44,186 shares of the company's stock, valued at $13,025,590.94. This trade represents a 16.56 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 69,341 shares of company stock valued at $20,644,335 over the last quarter. 0.69% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

AMGN has been the topic of a number of recent analyst reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Redburn Partners reduced their target price on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Truist Financial cut their price target on Amgen from $333.00 to $298.00 and set a "hold" rating on the stock in a research note on Wednesday, January 8th. William Blair restated an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Finally, Leerink Partners cut their price target on Amgen from $349.00 to $302.00 in a research note on Wednesday, November 27th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $314.95.

Amgen Stock Up 1.4 %

NASDAQ AMGN traded up $4.38 during trading on Wednesday, hitting $316.57. The company's stock had a trading volume of 2,628,966 shares, compared to its average volume of 2,544,250. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The company has a market cap of $170.06 billion, a PE ratio of 41.93, a P/E/G ratio of 2.63 and a beta of 0.56. The business's 50 day simple moving average is $283.80 and its 200-day simple moving average is $299.78. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date is Friday, May 16th. Amgen's dividend payout ratio (DPR) is 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.